MEDICAL POLICY – 8.01.62
Electronic Brachytherapy for Nonmelanoma Skin Cancer

Effective Date: Sept. 1, 2017
Last Revised: Aug. 22, 2017

Introduction
Brachytherapy is a type of radiation therapy. “Brachy-” means “short,” so brachytherapy is a way of giving radiation that doesn’t travel through very much other tissues to reach the cancerous tissue. Electronic brachytherapy is being studied as a treatment for skin cancer other than melanoma. Surgery is usually used to treat nonmelanoma skin cancer. With electronic brachytherapy, a high-dose x-ray is used to deliver radiation directly to the cancerous area. Typically, a mold is made and then placed over the treatment area. A probe — the source of radiation — is inserted into the mold so that the source touches the skin. The radiation is then activated. Once the radiation is delivered, the source is turned off, and the probe and mold are removed. Several sessions are required to complete the treatment. Electronic brachytherapy for nonmelanoma skin cancer is unproven. More studies are needed to see if this treatment is as good as or better than surgery and other types of radiation treatment.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
**Treatment**

**Investigational**

Electronic brachytherapy (nonmelanoma skin cancer)  

Electronic brachytherapy for the treatment of nonmelanoma skin cancer* is considered investigational.

*Note: Nonmelanoma skin cancer refers to squamous cell carcinoma and basal cell carcinoma. There are other less common types of skin cancer, such as T-cell lymphoma or Merkel cell tumor, which may have specific treatment options that are different from basal and squamous cell carcinomas and may need to be considered on an individual basis.

---

**Coding**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td></td>
</tr>
<tr>
<td>0394T</td>
<td>High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed</td>
</tr>
<tr>
<td>0395T</td>
<td>High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed</td>
</tr>
</tbody>
</table>

*Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).*

---

**Related Information**

**Benefit Application**

Electronic brachytherapy for the treatment of breast cancer is a covered diagnosis.

---

**Evidence Review**
Description

Electronic brachytherapy is a form of radiotherapy designed to deliver high-dose rate radiation to treat nonmelanoma skin cancer. This technique focuses a uniform dose of x-ray source radiation to the lesion with the aid of a shielded surface application.

Background

Nonmelanoma Skin Cancer

Squamous cell carcinoma and basal cell carcinoma are the most common types of nonmelanoma skin cancer in the United States, affecting between 1 and 3 million people per year\(^1\) and increasing at a rate of 3% to 8% per year.\(^1\) Other types (eg, T-cell lymphoma, Merkel cell tumor, basosquamous carcinoma, Kaposi sarcoma) are much less common. The primary risk factor for nonmelanoma skin cancer is sun exposure, with additional risk factors such as toxic exposures, other ionizing radiation exposure, and immunosuppression playing smaller roles.\(^2\) Although these cancers are rarely fatal, they can impact the quality of life, functional status, and physical appearance.

Treatment

Surgical

Treatment of nonmelanoma skin cancer is primarily surgical,\(^3\) and the choice of surgical procedure depends on the histologic type, size and location of the lesion. Patient preferences can also play a factor in surgical decisions due to cosmetic reasons, as well as the consideration of comorbidities and patient risk factors such as anticoagulation. Local excisional procedures, such as electrodessication and curettage or cryotherapy, can be used for low-risk lesions, while surgical excision is indicated for lesions that are not low risk. Mohs surgery is an excisional procedure that uses microscopic guidance to achieve greater precision and sparing of normal tissue. In patients who meet criteria for Mohs surgery, 5-year cure rates for basal cell cancer range from 98% to 99%,\(^4\) making Mohs surgery the preferred procedure for those who qualify.
Radiotherapy

Radiotherapy is indicated for certain nonmelanoma skin cancers that are not amenable to surgery. In some cases, this is due to the location of the lesion on the eyelid, nose, or other structures that make surgery more difficult and which may be expected to have a less desirable cosmetic outcome. In other cases, surgery may be relatively contraindicated due to clinical factors such as bleeding risk or advanced age. In elderly patients with a relatively large tumor that would require extensive excision, the benefit/risk ratio for radiotherapy may be considered to be favorable. The 5-year control rates for radiotherapy are in the range of 80% to 92%, which is lower than for surgical excision. A randomized controlled trial published in 1997 reported that radiotherapy for basal cell carcinoma resulted in greater numbers of persistent and recurrent lesions compared with surgical excision.

When radiotherapy is used for nonmelanoma skin cancer, the primary modality is external beam radiation. A number of different brachytherapy techniques have also been developed, including low-dose rate systems, Iridium-based systems, and HDR systems.

Electronic Brachytherapy

Electronic brachytherapy is a form of radiotherapy delivered locally. Available systems for the treatment of nonmelanoma skin cancers are designed to deliver HDR brachytherapy for the treatment of skin surface lesions. This technique is feasible for well-circumscribed, superficial tumors. It focuses a uniform dose of x-ray source radiation to the lesion with the aid of a shielded surface application.

A pliable mold is constructed of silicone or polymethyl-methacrylate and fitted to the tumor surface. This mold allows treatment to be delivered to nonflat surfaces such as the nose or ear. A radioactive source is then inserted into the mold to contact the tumor and deliver a uniform radiation dosage.

Potential advantages of this treatment modality compared with standard radiotherapy include a shorter treatment schedule and the avoidance of radioisotopes and a dedicated treatment vault.

Summary of Evidence

For individuals who have nonmelanoma skin cancer who receive electronic brachytherapy, the evidence includes a systematic review and case series. Relevant outcomes are overall survival,
disease-specific survival, change in disease status, and treatment-related morbidity. No controlled trials were identified that have compared electronic brachytherapy with alternative treatment options. Further, a 2016 systematic review of case series found local control rates ranging from 83% to 100% and recurrence rates ranging from 0% to 17%. In most studies, the recurrence rate was less than 5%. In the absence of controlled studies, conclusions cannot be drawn about the efficacy and safety of electronic brachytherapy compared with other treatments for nonmelanoma skin cancer. Controlled trials are needed in defined populations that compare electronic brachytherapy with alternatives, specifically other forms of radiotherapy or surgical approaches. The evidence is insufficient to determine the effects of the technology on health outcomes.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this policy are listed in Table 1.

Table 1. Summary of Key Ongoing Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01016899</td>
<td>Xoft Electronic Brachytherapy Clinical Protocol for the Primary Treatment of Non-Melanoma Skin Cancer</td>
<td>100</td>
<td>Feb 2016 (ongoing)</td>
</tr>
<tr>
<td>NCT02131805</td>
<td>Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma</td>
<td>26</td>
<td>May 2018</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

Denotes industry-sponsored or cosponsored trial.

Practice Guidelines and Position Statements

National Comprehensive Cancer Network

National Comprehensive Cancer Network guidelines on basal cell carcinoma (v.1.2017)\textsuperscript{13} and squamous cell skin cancer (v.1. 2017)\textsuperscript{14} both contain the following statement on electronic brachytherapy: “There is insufficient long-term efficacy and safety data to support the routine use of electronic brachytherapy.”
American Academy of Dermatology

Guidelines from the American Academy of Dermatology on nonmelanoma skin cancers are anticipated before the end of 2017.15

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

Regulatory Status

Electronic brachytherapy systems for the treatment of nonmelanoma skin cancers are designed to deliver high-dose rate brachytherapy to treat skin surface lesions. This technique focuses a uniform dose of x-ray source radiation to the lesion with the aid of a shielded surface application. The Esteya® Electronic Brachytherapy System (Nucletron BV) and the Xoft® Axxent® Electronic Brachytherapy System (iCAD, Nashua, NH) are 2 systems that have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process.

FDA product code: JAD.

References


<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/14/15</td>
<td>New Policy. Policy created with literature review through April 30, 2015. Electronic brachytherapy is considered investigational for the treatment of nonmelanoma skin cancer.</td>
</tr>
<tr>
<td>01/20/16</td>
<td>Coding update. New CPT codes 0394T-0395T, effective 1/1/16, added to policy.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply.
Scope: Medical policies are systematically developed Guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
• Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  • Qualified sign language interpreters
  • Written information in other formats (large print, audio, accessible electronic formats, other formats)
• Provides free language services to people whose primary language is not English, such as:
  • Qualified interpreters
  • Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance:

Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592, TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at:
https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)
Complaint forms are available at:

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost.
Call 800-722-1471 (TTY: 800-842-5357).

Arabic:
بكونه هذا الإشعار معلومات هامة، قد يكون هذا الإشعار معلومات مهمة ينصحون طبي أو
العملية التي تزيد الحصول عليها من خلال
Premera Blue Cross. هذه المعلومات لا تزداد الحصول على هذه المعلومات والعملية بناءً على
800-722-1471 (TTY: 800-842-5357)

中文 (Chinese):
本通知有重要的訊息。本通知可能有關於您透過 Premera Blue Cross 提交的
申請或保單的重要訊息。本通知可能會有重要日期，您可能需要在截止日期
之前採取行動，以保留您的健康保險或費用補貼。您有權利免費以您的母
語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357).

Oromo (Cushite):
Beekisini kun odeefannoo barbaachisaa qaba. Beekisii kun sagantaa
yooan karaa Premera Blue Cross tiin tajajila keessan ilaachiise
odeefannoo barbaachisaa qabaachuu danda’a. Guyyaawaan muurteessa
ta’an beekisaa kana keessatti ilaali. Tarii kaffaliiidaan deegaggarmuu
yooan tajajila fayyaaa keessaffii gyyaa dhumaa irratti waantaa raawwattaan
jiraa chuuh danda’a. Kaffalii irrii biilaas haallaa ta’een afan keessanii
odeefannoo argachuu fi deeggargaar argachuuf minga ni qabaattu.
Lakkoofsa bibiibii 800-722-1471 (TTY: 800-842-5357) ti bibibii.

Français (French):
Cet avis a d’importantes informations. Cet avis peut avoir d’importantes
informations sur votre demande ou la couverture par l’intermédiaire de
Premera Blue Cross. Le présent avis peut contenir des dates clés. Vous
devrez peut-être prendre des mesures par certains délais pour maintenir
votre couverture de santé ou d’aide avec les coûts. Vous avez le droit
d’obtenir cette information et de l’aide dans votre langue à aucun coût.
Appelez le 800-722-1471 (TTY: 800-842-5357).

Kreyòl ayisyen (Creole):
Avi sila a gen Enfòmasyon Enpòtan ladan. Avi sila a kapab genyen
enfòmasyon enpòtan konsènan aplikasyon w lan oswa konèsan
kouvèti asirans lan atravè Premera Blue Cross. Kapab genyen dat ki enpòtan
nan avi sila a. Ou ka gen pou pran kék aksyon avan sëten dat limit pou ka
kenbe kouvèti asirans sante w la oswa pou yo ka ede w akèv depans yo.
Se dwa w pou resewa enfòmasyon sa a ak asistantis nan lang ou paale a,
san ou pa gen pou peye pou sa. Rate nan 800-722-1471
(TTY: 800-842-5357).

Deutsche (German):
Diese Benachrichtigung enthält wichtige Informationen. Diese
Benachrichtigung enthält unter Umständen wichtige Informationen
bezüglich Ihres Antrags auf Krankenversicherungsschutz durch Premera
Blue Cross. Suchen Sie nach eventuellen wichtigen Terminen in dieser
Benachrichtigung. Sie könnten bis zu bestimmten Stichtagen handeln
müssen, um Ihren Krankenversicherungsschutz oder Hilfe mit den Kosten
zu behalten. Sie haben das Recht, kostenlose Hilfe und Informationen
in Ihrer Sprache zu erhalten. Rufen Sie an unter 800-722-1471
(TTY: 800-842-5357).

Hmooj (Hmong):
Tsaab ntawv tsjay xo no muaj cov ntsiab lus tseem ceeb. Tej zaum
tsab ntawv tsjay xo no muaj cov ntsiab lus tseem ceeb bokk koj
daim ntawv thov kev pab los yoy koj khov kev pab cuam los ntawm Premera Blue
Cross. Tej zaum muaj cov hnbv tseem ceeb uas tuu rau hav daim
ntawv no. Tej tej koj koy juuv tuu uae yam uas peb koj uas tsip
dhau cov caij nyong uas teev tsip rau hav daim ntawv no mas koy
tsab ntawv tuu tais kev pab cuam kho moob los yoy kev pab tej
ntawm koj. Koy muaj caij kom laww muab cov ntsiab lus no uas tuu
muab sa u koj hom lus pub dawb rau koj. Hu rau 800-722-1471
(TTY: 800-842-5357).

Ilokko (Ilocano):
Daytoy a Pakdaak ket naglaon iti Napateg nga Impomarsan. Daytoy a
pakdaak mabalin nga adda ket naglaon iti napateg nga impomarsan
maipangegg iti aplikasyonu wengi coverage babaen iti Premera Blue
Cross. Daytoy ket mabalin dagiti importante a pelsa iti daytoy a pakdaak.
Mabalin nga adda sumbang nga aramidwenu nga adda amsak dagiti
partikular a naituding nga odaffa nga adda amsak tapangaliniye do coverage ti
talay-eddo wengi tongk dagatig yastos. Adda karbenganyo a mangala iti
daytoy nga impomarsan ken tongk ti bukodyo a pagasao nga awan ti

Italiano (Italian):
Questo avviso contiene informazioni importanti. Questo avviso può contenere
informazioni importanti sulla tua domanda o copertura attraverso Premera
Blue Cross. Potrebbero esserci date chiave in questo avviso. Potrebbe
essere necessario un tuo intervento entro una scadenza determinata per
consentirti di mantenere la tua copertura o sovvenzione. Hai il diritto
di ottenere queste informazioni e assistenza nella tua lingua gratuitamente.
Chiamate 800-722-1471 (TTY: 800-842-5357).

037338 (07-2016)
Japanese (Japanese):
この通知には重要な情報が含まれています。この通知には、Premera Blue Crossの申請または補償範囲に関する重要な情報が含まれています。この通知には記載されている可能性がある重要な日付をご確認ください。健康保険や医療サービスを維持するには、特定の期日までに行動を取らなければならない場合があります。ご希望の言語による情報とサポートが無料で提供されます。0800-722-1471 (TTY: 800-842-5357)までお電話ください。

한국어 (Korean):
본 통지서에는 중요한 정보가 들어 있습니다. 즉 이 통지서는 귀하의 신청에 관하여 그리고 Premera Blue Cross를 통해 커버리지에 관한 정보를 포함하고 있는 것입니다. 본 통지서에는 핵심이 되는 날짜들이 있을 수 있습니다. 귀하의 신청의 건강 커버리지에 대한 유의점이 있습니다. 따라서 일정한 마감일까지 조치를 취해야 할 필요가 있을 수 있습니다.

한국어 (Khmer):
ក្រៅពីការប្រឈមសេវាកម្មដែលខ្លួនឯងឈ្នះចំពោះការរៀបចំស្តើារនេះនេះ Premera Blue Cross និងការធ្វើការប្រឈមសេវាកម្មតាមរយៈលេខ 800-722-1471 TTY: 800-842-5357 តើក្រោយការប្រឈមសេវាកម្មមានរក្សាទុកមានទូរទស្សន៍ថ្នាក់ដែលទាក់ទងនឹងការប្រឈមសេវាកម្មដែលខ្លួនឯងឈ្នះ។

Polski (Polish):

Português (Portuguese):
Este aviso contém informações importantes. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do Premera Blue Cross. Poderão existir dados importantes neste aviso. Talvez seja necessário que você tome providências dentro de determinados prazos para manter sua cobertura de saúde e ajuda de custos. Você tem o direito de obter esta informação e ajuda em seu idioma e sem custos. Ligue para 800-722-1471 (TTY: 800-842-5357).

Română (Romanian):

Русский (Russian):
Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В этом уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется привести к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами.

Українська (Ukrainian):
Це повідомлення містить важливу інформацію, що повідомлення може містити важливу інформацію про Ваше звернення щодо страховального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки в конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дзвоніть за номером телефону 800-722-1471 (TTY: 800-842-5357).